Lacidipina Eg

Lacidipine, the active ingredient in Lacidipina Eg, is a calcium channel blocker presented as an oral dosage form for oral use. It is used to treat hypertension in adult patients. GNH USA supplies Lacidipina Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine belongs to the calcium channel blocker class and is employed in the management of elevated blood pressure. - Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - Isolated systolic hypertension: improves vascular tone and reduces systolic pressure in older adults. - Secondary hypertension: assists in blood‑pressure control when hypertension is due to another underlying condition.

Lacidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, often on the face. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Nausea or abdominal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzymes. - Myocardial infarction: rare but possible cardiac event. - Arrhythmias: irregular heart rhythms. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy with Lacidipine, several safety considerations should be observed. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Cardiac evaluation: review history of heart failure or recent myocardial infarction. - Concomitant antihypertensives: adjust doses to prevent additive effects. - Hepatic impairment: use with caution and consider dose adjustment. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Lacidipine plasma levels. - Other calcium‑channel blockers: additive vasodilatory effect leading to hypotension. - Grapefruit juice: can raise drug concentration and risk of side effects. - Concurrent antihypertensives (e.g., ACE inhibitors, beta‑blockers): may cause excessive blood‑pressure reduction. - Digoxin: increased risk of cardiac toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance orthostatic hypotension. - NSAIDs: can blunt antihypertensive response. - Alcohol: may potentiate dizziness and hypotension. - Lipid‑lowering agents (e.g., statins): monitor for altered metabolism.